Checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) or its ligand (PD-L1) are currently available for those that progressed on first-line platinum-based chemotherapy and those that are cisplatin-ineligible and have a PD-L1 positive tumor. Here, CD274 is linked to neoplasm.